secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001493152-26-016865
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics FY2025 revenue up 16% to $17.5M; operating loss widens to $19.9M
--------------------------------------------------------------------------------

- FY2025 revenue $17.5M, +16% YoY from $15.0M; driven by sleep testing services and SCN acquisition.
- Operating loss $19.9M vs $11.2M in FY2024; expenses rose to $30.4M on SCN integration costs.
- Cash and equivalents $2.0M at Dec. 31, 2025; subsequent financing raised $6.8M in gross proceeds.
- Gross margin held at 60%; business pivoting from VIP enrollment to sleep provider acquisitions and alliances.
- Management targets achieving cash-flow-positive operations by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/0001493152-26-016865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-016865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer